CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.

Melchardt, T, Hufnagl, C, Magnes, T, Weiss, L, Hutarew, G, Neureiter, D, Schlattau, A, Moser, G, Gaggl, A, Tränkenschuh, W, Greil, R, Egle, A.

http://www.ncbi.nlm.nih.gov/pubmed/26475344